Chinese biotech giant WuXi AppTec raises 2026 outlook after profit surge

WuXi AppTec raised its full-year revenue guidance after its net profit surged 62.4 per cent in the first nine months of 2026, while revenue rose 38.6 per cent on strong demand for its drug development and manufacturing services. The Chinese pharmaceutical research services provider’s net profit reached 19.16 billion…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.